Original Article
A cost-consequence analysis of the preferential use of secukinumab versus adalimumab for the treatment of psoriatic arthritis
Análisis de las consecuencias en materia de costos del uso preferencial del secukinumab en comparación con el adalimumab para el tratamiento de la artritis psoriásica
Leído
5919
Vecesse ha leído el artículo
3841
Total PDF
2078
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 11 | 208 | 32 | 240 |
| 2025 10 | 19 | 60 | 79 |
| 2025 9 | 0 | 89 | 89 |
| 2025 8 | 0 | 71 | 71 |
| 2025 7 | 0 | 52 | 52 |
| 2025 6 | 3 | 15 | 18 |
| 2025 5 | 78 | 52 | 130 |
| 2025 4 | 75 | 23 | 98 |
| 2025 3 | 55 | 31 | 86 |
| 2025 2 | 52 | 47 | 99 |
| 2025 1 | 54 | 48 | 102 |
| 2024 12 | 43 | 47 | 90 |
| 2024 11 | 32 | 39 | 71 |
| 2024 10 | 31 | 35 | 66 |
| 2024 9 | 34 | 30 | 64 |
| 2024 8 | 53 | 58 | 111 |
| 2024 7 | 42 | 45 | 87 |
| 2024 6 | 30 | 30 | 60 |
| 2024 5 | 42 | 31 | 73 |
| 2024 4 | 35 | 37 | 72 |
| 2024 3 | 30 | 29 | 59 |
| 2024 2 | 21 | 30 | 51 |
| 2024 1 | 23 | 30 | 53 |
| 2023 12 | 34 | 27 | 61 |
| 2023 11 | 57 | 67 | 124 |
| 2023 10 | 46 | 41 | 87 |
| 2023 9 | 142 | 55 | 197 |
| 2023 8 | 153 | 22 | 175 |
| 2023 7 | 27 | 2184 | 2211 |
| 2023 6 | 27 | 34 | 61 |
| 2023 5 | 29 | 35 | 64 |
| 2023 4 | 16 | 22 | 38 |
| 2023 3 | 48 | 25 | 73 |
| 2023 2 | 40 | 25 | 65 |
| 2022 1 | 24 | 15 | 39 |
| 2022 12 | 61 | 37 | 98 |
| 2022 11 | 61 | 36 | 97 |
| 2022 10 | 85 | 33 | 118 |
| 2022 9 | 65 | 40 | 105 |
| 2022 8 | 66 | 40 | 106 |
| 2022 7 | 46 | 45 | 91 |
| 2022 6 | 44 | 40 | 84 |
| 2022 5 | 47 | 55 | 102 |
| 2022 2 | 0 | 2 | 2 |
Mostrar todo
